BMS-986504 + nab-paclitaxel + gemcitabine

This is a combination therapy consisting of **BMS-986504**, **nab-paclitaxel**, and **gemcitabine**. - **BMS-986504** is a first-in-class, MTA-cooperative, selective inhibitor of protein arginine methyltransferase 5 (**PRMT5**), specifically targeting the PRMT5-methylthioadenosine (MTA) complex that forms in cancer cells with homozygous methylthioadenosine phosphorylase (**MTAP**) deletion. This selective targeting leads to cancer cell death while sparing normal cells[1][2][4][6]. - **Nab-paclitaxel** (nanoparticle albumin-bound paclitaxel) is a microtubule inhibitor (antineoplastic agent) that disrupts microtubule function and cell division. - **Gemcitabine** is a nucleoside analog (antimetabolite) that inhibits DNA synthesis, leading to apoptosis in dividing cells. The combination is being developed and tested primarily for **untreated metastatic pancreatic ductal adenocarcinoma with MTAP deletion** but may have relevance to other MTAP-deleted cancers including non-small cell lung cancer (NSCLC) and glioblastoma[1][2][3][6].

Other names

Abraxane + Gemzar + BMS-986504